1-4 of 4
Halis Kaan Akturk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population

G. Todd Alonso, Taylor M. Triolo, Halis Kaan Akturk, Meghan E. Pauley, Marisa Sobczak, Gregory P. Forlenza, Casey Sakamoto, Laura Pyle, Brigitte I. Frohnert
Journal: Diabetes Care
Diabetes Care 2023;46(6):1218–1222
DOI: https://doi.org/10.2337/dc22-2121
Published: 06 April 2023
View article titled, Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population
Click here to open pdf in another window PDF for Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population
Journal Articles

Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study

Anagha Champakanath, Halis Kaan Akturk, G. Todd Alonso, Janet K. Snell-Bergeon, Viral N. Shah
Journal: Diabetes Care
Diabetes Care 2022;45(3):750–753
DOI: https://doi.org/10.2337/dc21-2004
Published: 12 January 2022
View article titled, Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
Click here to open pdf in another window PDF for Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
Journal Articles

Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes

Halis Kaan Akturk, Janet Snell-Bergeon, Gregory L. Kinney, Anagha Champakanath, Andrew Monte, Viral N. Shah
Journal: Diabetes Care
Diabetes Care 2022;45(2):481–483
DOI: https://doi.org/10.2337/dc21-1730
Published: 08 December 2021
View article titled, Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes
Click here to open pdf in another window PDF for Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes
Journal Articles

The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes

Klara R. Klein, Jennifer L.R. Freeman, Imogene Dunn, Chris Dvergsten, M. Sue Kirkman, John B. Buse, Carmen Valcarce, SimpliciT1 research group, John B. Buse, Klara R. Klein, M. Sue Kirkman, Katherine A. Bergamo, Elizabeth H. Harris, Jean M. Dostou, Laura A. Young, Sriram Machineni, Alex M. Kass, Jamie C. Diner, Milana Dezube, Virginia C. Purrington, Julie M. Uehling, Rachael M. Fraser, Katherine R. Schuch, Jennifer V. Rowell, Ali Qamar, K. Jean Lucas, Luke Snedaker, Stephanie Hoover, Justin Smith, Paul Becton, Jeffrey Hainsworth, Timothy S. Bailey, Juan Pablo Garcia-Naranjo, Niki Nguyen, Bruce W. Bode, Jennifer M. Boyd, Betsy Childs, Pablo Mora, Allison Camacho, Carl D. Vance, Karen Lugo, Anuj Bhargava, Kirstie Stifel, Lisa B. Connery, Birjis Khan, Simone D. Smith, John Parker, Kathryn Zweier, Emily Kronenfeld, Brittany Savoca, Viral N. Shah, Prakriti Joshee, Shivani Dixit, Hal Joseph, Halis Kaan Akturk, Subbulaxami Trikudanathan, Dori Khakpour, Julia Chang, Anne Peters, Pejman Cohan, Mark Harmel, Wendy S . Lane
Journal: Diabetes Care
Diabetes Care 2021;44(4):960–968
DOI: https://doi.org/10.2337/dc20-2684
Published: 23 February 2021
View article titled, The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
Click here to open pdf in another window PDF for The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes